Cartesian Therapeutics, Inc. — fact timeline

Cartesian Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-12 meeting.

“Proposal 3 - Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 24,144,742 6,157 637 — Based on the votes set forth above, the stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.”

Cartesian Therapeutics, Inc. shareholders approved Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company's named executive officers. at the 2026-06-12 meeting.

“Proposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 13,659,709 136,217 6,033,199 4,322,411 Based on the votes set forth above, the stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers.”

Cartesian Therapeutics, Inc. shareholders approved Election of three Class I Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. at the 2026-06-12 meeting.

“Proposal 1 - Election of three Class I Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Michael Singer, M.D., Ph.D. 11,745,619 8,083,506 4,322,411 Timothy A. Springer, Ph.D. 18,665,163 1,163,962 4,322,411 Patrick Zenner, M.B.A 12,168,919 7,660,206 4,322,411 Based on the votes set forth above, each director nominee was duly elected to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.”

Cartesian Therapeutics, Inc. entered into Loan and Security Agreement with certain financial institutions party thereto as lenders, K2 HealthVentures LLC, as administrative agent and Ankura Trust Company, LLC, as collateral trustee valued at up to $150.0 million (effective 2026-05-22).

“On May 22, 2026, Cartesian Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, Cartesian Bio, LLC, as borrowers (“Borrowers”), entered into a Loan and Security Agreement (the “Loan Agreement”) with certain financial institutions party thereto as lenders (the “Lenders”), K2 HealthVentures LLC, as administrative agent (in such capacity, the “Administrative Agent”) and Ankura Trust Company, LLC, as collateral trustee (in such capacity, the “Collateral Trustee”). The Loan Agreement provides for senior secured term loans in an aggregate principal amount of up to $150.0 million”

Milos Miljkovic resigned as Chief Medical Officer at Cartesian Therapeutics, Inc..

“On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.”

Cartesian Therapeutics, Inc. reported three months ended March 31, 2026 results: net income -39,200,000, EPS -1.46.

“Net loss was $39.2 million, or $1.46 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2026, compared to net loss of $17.7 million, or $0.68 net loss per share allocable to common stockholders (basic), for the three months ended March 31, 2025.”

Cartesian Therapeutics, Inc. reported financial results for the year ended December 31, 2025.

“On March 9, 2026, Cartesian Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025.”

Cartesian Therapeutics, Inc.: Adopted an updated version of the Code of Business Conduct and Ethics, effective December 16, 2025, superseding prior code (effective 2025-12-16).

“On December 16, 2025, the Board adopted an updated version of the Cartesian Therapeutics, Inc. Code of Business Conduct and Ethics (the “Code”), effective as of such date.”

Cartesian Therapeutics, Inc.: Board approved amendment and restatement of bylaws to include references to the position of Lead Independent Director (effective 2025-10-29).

“On October 29, 2025, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, which became effective the same day. The Amended and Restated Bylaws now include appropriate references to the position of Lead Independent Director of the Board.”

Metin Kurtoglu departed as Chief Technology Officer at Cartesian Therapeutics, Inc..

“Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025”

Kemal Malik was appointed as Class II director at Cartesian Therapeutics, Inc..

“On July 1, 2024, the Board of Directors (the “Board”) of the Company appointed Kemal Malik, MBBS as a Class II director, and fixed the size of the Board at nine directors.”

Cartesian Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 8, 2024, Cartesian Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”

Metin Kurtoglu was appointed as Chief Technology Officer at Cartesian Therapeutics, Inc..

“Under the terms of the Kurtoglu Employment Agreement, Dr. Kurtoglu will serve as the Company’s Chief Technology Officer, is entitled to receive an annual base salary of $440,000 and will be eligible for an annual performance bonus targeted at 40% of his annual base salary beginning in 2024.”

Christopher Jewell was appointed as Chief Scientific Officer at Cartesian Therapeutics, Inc..

“As previously announced, on November 13, 2023, Cartesian Therapeutics, Inc. (the “Company”) appointed Christopher Jewell, Ph.D., age 43, to serve as the Company’s Chief Scientific Officer.”

Cartesian Therapeutics, Inc.: Amended Certificate of Designation to change automatic conversion timing to 5:00 p.m. eight business days after stockholder approval of the Conversion Proposal (effective 2024-03-26).

“On March 26, 2024, the Company, with the consent of the holders of Series A Preferred Stock required thereby, amended the Certificate of Designation (such amendment, the “Amendment to the Certificate of Designation”) such that the Automatic Conversion (as defined in the Certificate of Designation) will occur at 5:00 p.m. eight business days following stockholder approval of the Conversion Proposal (defined below).”

Cartesian Therapeutics, Inc. shareholders approved Approval of the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1 or 2 (the "Adjournment Proposal"). at the 2024-03-27 meeting.

“Proposal 3: Approval of the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1 or 2 (the "Adjournment Proposal"). Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 114,948,498 7,889,418 332,599 —”

Cartesian Therapeutics, Inc. shareholders approved Approval of an amendment to the Company's restated certificate of incorporation, as amended (the "Charter"), to effect a reverse stock split of the Company's issued and outstanding Common Stock, at a ratio in the range of 1-for-20 and 1-for-30, with such ratio to be determined at the discretion of t at the 2024-03-27 meeting.

“Proposal 2: Approval of an amendment to the Company's restated certificate of incorporation, as amended (the "Charter"), to effect a reverse stock split of the Company's issued and outstanding Common Stock, at a ratio in the range of 1-for-20 and 1-for-30, with such ratio to be determined at the discretion of the Board of Directors (the "Board") of the Company (the "Reverse Stock Split Proposal"). Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 114,747,625 6,237,877 2,185,013 —”

Cartesian Therapeutics, Inc. shareholders approved Approval of the issuance of shares of the Company's Common Stock upon conversion of the Series A Preferred Stock (the "Conversion Proposal"). at the 2024-03-27 meeting.

“Proposal 1: Approval of the issuance of shares of the Company's Common Stock upon conversion of the Series A Preferred Stock (the "Conversion Proposal"). Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 87,791,910 2,865,444 75,914 25,713,608”

Cartesian Therapeutics, Inc. terminated License and Development Agreement with Audentes Therapeutics, Inc. ("Astellas") (effective 2024-06-06).

“On March 8, 2024, Cartesian Therapeutics, Inc. (the “Company”) received notice from Audentes Therapeutics, Inc. (“Astellas”) of Astellas’ termination of the License and Development Agreement, dated January 8, 2023, by and between the Company and Astellas (the “Agreement”).”

Cartesian Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.

“Cartesian Therapeutics, Inc. announced its financial results for the year ended December 31, 2023.”

Cartesian Therapeutics, Inc. entered into Lease Agreement with 7495 RP, LLC valued at Initial base rent of $902,353 per year for approximately 20,000 leasable square feet (effective 2024-02-28).

“On February 28, 2024, Cartesian Therapeutics, Inc. (the “Company”) entered into a lease agreement with 7495 RP, LLC (the “Landlord”), pursuant to which the Company agreed to lease from the Landlord the manufacturing space located at 7495 New Horizon Way, Frederick, Maryland 21702 (the “Lease Agreement”).”

Aymeric Sallin resigned as Director at Cartesian Therapeutics, Inc..

“On February 28, 2024, Aymeric Sallin, a member of the Board of Directors (the “Board”) of the Company, notified the Company of his resignation from the Board, effective immediately, to pursue other opportunities.”

Cartesian Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“January 17, 2024, Cartesian Therapeutics, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1). The notification from Nasdaq has no immediate effect on the listing of the Company’s Common S”

Scott D. Myers resigned as member of the Board of Directors at Cartesian Therapeutics, Inc..

“On November 21, 2023, Scott D. Myers, a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board, effective immediately, to pursue other opportunities.”

Cartesian Therapeutics, Inc.: Company amended its restated certificate of incorporation to change corporate name to Cartesian Therapeutics, Inc (effective 2023-11-13).

“On November 13, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to the Charter to change its corporate name to Cartesian Therapeutics, Inc.”

Cartesian Therapeutics, Inc. completed an acquisition involving Cartesian Therapeutics, Inc. for 6,723,662 shares of the common stock of Selecta and 384,930.725 shares of Series A Preferred Stock (closed 2023-11-13).

“Agreement and Plan of Merger On November 13, 2023, Selecta Biosciences, Inc., a Delaware corporation (“Selecta” or the “Company”), acquired Cartesian Therapeutics, Inc., a Delaware corporation (“Cartesian”), in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the “Merger Agreement”), by and among Selecta, Sakura Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Selecta (“First Merger Sub”), Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Selecta (“Second Merger Sub”), and Cartesian.”

Cartesian Therapeutics, Inc. entered into Merger Agreement with Selecta Biosciences, Inc..

“Pursuant to the Merger Agreement, Selecta has agreed to hold a stockholders’ meeting to submit the following matters to its stockholders for their consideration”

Chris Jewell was appointed as Chief Scientific Officer at Cartesian Therapeutics, Inc..

“the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.”

Milos Miljkovic was appointed as Chief Medical Officer at Cartesian Therapeutics, Inc..

“the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.”

Metin Kurtoglu was appointed as Chief Operating Officer at Cartesian Therapeutics, Inc..

“the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.”

Lloyd Johnston resigned as Chief Operations Officer at Cartesian Therapeutics, Inc..

“each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively”

Kei Kishimoto resigned as Chief Scientific Officer at Cartesian Therapeutics, Inc..

“each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively”

Peter Traber resigned as Chief Medical Officer at Cartesian Therapeutics, Inc..

“each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively”

Cartesian Therapeutics, Inc. amended License and Development Agreement with Swedish Orphan Biovitrum AB (publ.) valued at The Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi’s (effective 2023-10-31).

“On October 31, 2023, Selecta Biosciences, Inc. (the “Company”) and Swedish Orphan Biovitrum AB (publ.) (“Sobi”) entered into Amendment No. 1 (the “Amendment”) to the License and Development Agreement (as so amended, the “Agreement”) by and between the Company and Sobi. Pursuant to the Amendment, the Company granted Sobi an exclusive license to manufacture ImmTOR solely in connection with Sobi’s development of SEL-212 under the Agreement and is transferring certain contracts and manufacturing equipment to Sobi. Additionally, in connection with entry into the Amendment, Sobi agreed to make employment offers to certain of the Company’s employees engaged in ImmTOR manufacturing activities on or prior to a specified date, and the Company agreed not to terminate the employment of such employees prior to such specified date.”

Peter Traber changed role as Chief Medical Officer at Cartesian Therapeutics, Inc..

“Peter Traber, the Company’s Chief Medical Officer, has agreed to serve as a consultant to Sobi and move to part-time status as the Company’s Chief Medical Officer, each effective as of November 6, 2023.”

Cartesian Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-16 meeting.

“Proposal 4 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 101,433,021 923,103 34,836 —”

Cartesian Therapeutics, Inc. shareholders rejected Approval of an amendment to the Company's Restated Certificate of Incorporation to change the vote required for stockholders to approve an amendment to the bylaws from two-thirds to a majority at the 2023-06-16 meeting.

“Proposal 3 - Approval of an amendment to the Company's Restated Certificate of Incorporation, as amended, to change the vote required for stockholders to approve an amendment to the Company's Amended and Restated Bylaws from two-thirds to a majority of the outstanding shares of capital stock of the Company entitled to vote thereon. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 67,852,901 1,742,501 301,325 32,494,233”

Cartesian Therapeutics, Inc. shareholders approved Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company's named executive officers at the 2023-06-16 meeting.

“Proposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company's named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 63,731,591 5,090,940 1,074,196 32,494,233”

Cartesian Therapeutics, Inc. shareholders approved Election of three Class I Directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-06-16 meeting.

“Proposal 1 - Election of three Class I Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Scott D. Myers 57,117,703 12,779,024 32,494,233 Timothy A. Springer, Ph.D. 60,365,992 9,530,735 32,494,233 Patrick Zenner 59,798,777 10,097,950 32,494,233”

Cartesian Therapeutics, Inc. amended Fourth Amendment to Loan and Security Agreement with Oxford Finance LLC; Silicon Valley Bank (effective 2023-03-31).

“On March 31, 2023, Selecta Biosciences, Inc. (the “Company”) entered into a Fourth Amendment to Loan and Security Agreement (the “Fourth Amendment”),which amended that certain Loan and Security Agreement, dated August 31, 2020, between the Company, Oxford Finance LLC, as collateral agent and as a lender, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)) (“Silicon Valley Bank”) as a lender”

Göran A. Ando retired as Director at Cartesian Therapeutics, Inc..

“On January 4, 2023, Göran A. Ando, M.D., a member of the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”), notified the Company that he is retiring from the Company’s Board effective immediately.”

Blaine Davis was appointed as Chief Financial Officer at Cartesian Therapeutics, Inc..

“On November 22, 2022, the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”) appointed Blaine Davis as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Davis’s full-time employment with the Company on November 28, 2022 (the “Effective Date”).”

Cartesian Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.

“Selecta Biosciences, Inc. announced its financial results for the quarter ended September 30, 2022.”

Ann K. Donohue resigned as interim principal financial officer and principal accounting officer at Cartesian Therapeutics, Inc..

“Ann K. Donohue resigned from her duties as the Company’s interim principal financial officer and principal accounting officer, effective as of the Effective Date, and will continue to serve as the Company’s Vice President, Finance moving forward.”

Kevin Tan was appointed as Chief Financial Officer at Cartesian Therapeutics, Inc..

“On September 20, 2021, Selecta Biosciences, Inc. (the “Company”) announced that the Board of Directors (the “Board”) of the Company has appointed Kevin Tan as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Tan’s full-time employment with the Company on September 20, 2021”